BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:18:56 PM | Browse: 158 | Download: 773
 |
Received |
|
2024-09-12 08:11 |
|
Peer-Review Started |
|
2024-09-12 08:11 |
|
First Decision by Editorial Office Director |
|
2025-01-16 12:33 |
|
Return for Revision |
|
2025-01-16 12:33 |
|
Revised |
|
2025-01-25 06:11 |
|
Publication Fee Transferred |
|
2025-01-26 10:02 |
|
Second Decision by Editor |
|
2025-02-13 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-13 07:06 |
|
Articles in Press |
|
2025-02-13 07:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-07 02:21 |
|
Publish the Manuscript Online |
|
2025-03-25 16:18 |
| ISSN |
1948-5204 (online) |
| Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian-Lin Lu, Yuan Cheng, Zi-Ling Xu, Gui-Xiang Qian, Ming-Tong Wei and Wei-Dong Jia |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Key Research and Development Projects of Anhui Province |
202104j07020048 |
| National Key Research and Development Program of China |
2022YFA1304504 |
|
| Corresponding Author |
Wei-Dong Jia, MD, PhD, Professor, Department of Hepatic Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, China. jwd1968@ustc.edu.cn |
| Key Words |
Hepatocellular carcinoma; Hepatitis B virus; Postoperative adjuvant therapy; Immune checkpoint inhibitors; Anti-angiogenesis |
| Core Tip |
The postoperative combined therapy with anti-programmed death 1/anti-programmed death ligand 1 and anti-vascular endothelial growth factor receptor agents has not been shown to be effective but not significant in reducing early recurrence in patients with hepatitis B virus-associated hepatocellular carcinoma. And thorough evaluation and close monitoring of liver function and hepatitis B-related markers in patients with hepatitis B virus-associated hepatocellular carcinoma are critical when implementing this combined treatment approach. |
| Publish Date |
2025-03-25 16:18 |
| Citation |
Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 101371 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/101371.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.101371 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
